Legal Representation
Attorney
Andrew D. Price
USPTO Deadlines
Next Deadline
945 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-02-08)
Due Date
February 08, 2028
Grace Period Ends
August 08, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 20, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Dec 28, 2022 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Feb 8, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Nov 30, 2021 | ISPO | Z | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST |
| Nov 24, 2021 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED |
| Nov 23, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Nov 23, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Nov 3, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Oct 19, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Oct 6, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Oct 6, 2021 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Oct 6, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Oct 6, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Oct 4, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Jun 24, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Jun 17, 2021 | ALIE | A | ASSIGNED TO LIE |
| Jun 10, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 29, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Mar 13, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer, viral infections, autoimmune diseases, and tumorous diseases, excluding ophthalmic pharmaceutical preparations; biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of tumorous diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of cancer, viral infections, autoimmune diseases, tumorous diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; medical diagnostic reagents used in connection with drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; medical diagnostic reagents used in connection with protein engineering and biological drug development
Class 042
Scientific and technological services, namely, pharmaceutical research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; protein engineering and biological drug development; provision of information and consultancy in relation to the aforesaid services
Classification
International Classes
005
042